RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+0.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.56B
AUM Growth
+$7.56B
(-3.8%)
Cap. Flow
+$595M
Cap. Flow
% of AUM
7.87%
Top 10 Holdings %
Top 10 Hldgs %
53.85%
Holding
87
New
11
Increased
24
Reduced
6
Closed
9
Top Buys
| 1 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$130M |
| 2 |
Recursion Pharmaceuticals
RXRX
|
$115M |
| 3 |
Arcellx
ACLX
|
$88.5M |
| 4 |
Avidity Biosciences
RNA
|
$86.5M |
| 5 |
Biogen
BIIB
|
$56M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$91.9M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$54.6M |
| 3 |
Cytek Biosciences
CTKB
|
$45.7M |
| 4 |
VXRT
Vaxart
VXRT
|
$20M |
| 5 |
EyePoint Pharmaceuticals
EYPT
|
$19.4M |
Sector Composition
| 1 | Healthcare | 99.86% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $1.38B | 18.23% | 10,108,400 | – | – |
|
2
Vaxcyte
PCVX
$4B
| $619M | 8.19% | 8,203,754 | – | – |
|
3
Janux Therapeutics
JANX
$1.37B
| $384M | 5.08% | 9,165,652 | – | – |
|
4
Legend Biotech
LEGN
$6.41B
| $332M | 4.4% | 7,506,934 +645,837 | +9% | +$28.6M |
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $250M | 3.3% | 6,084,412 +754,000 | +14% | +$31M |
|
|
6
Biogen
BIIB
$19.4B
| $228M | 3.01% | 982,139 +241,412 | +33% | +$56M |
|
|
CLYM
7
Climb Bio, Inc. Common Stock
CLYM
$151M
| $223M | 2.95% | 31,419,267 +18,268,418 | +139% | +$130M |
|
8
RxSight
RXST
$370M
| $222M | 2.94% | 3,694,825 +252,000 | +7% | +$15.2M |
|
|
9
Avidity Biosciences
RNA
$5.99B
| $221M | 2.92% | 5,400,408 +2,118,228 | +65% | +$86.5M |
|
10
Dyne Therapeutics
DYN
$1.92B
| $213M | 2.82% | 6,049,204 +1,094,425 | +22% | +$38.6M |
|
11
Geron
GERN
$893M
| $196M | 2.59% | 46,202,425 | – | – |
|
12
PepGen
PEPG
$38M
| $171M | 2.26% | 10,689,545 | – | – |
|
13
Tyra Biosciences
TYRA
$675M
| $167M | 2.2% | 10,416,609 | – | – |
|
14
Evolent Health
EVH
$1.12B
| $163M | 2.15% | 8,514,862 +2,778,730 | +48% | +$53.1M |
|
15
Edgewise Therapeutics
EWTX
$1.51B
| $160M | 2.12% | 8,909,091 | – | – |
|
16
NewAmsterdam Pharma
NAMS
$2.71B
| $155M | 2.05% | 8,064,000 +200,000 | +3% | +$3.84M |
|
|
17
Recursion Pharmaceuticals
RXRX
$2.04B
| $115M | 1.53% | +15,384,615 | New | +$115M |
|
18
89bio
ETNB
$1.34B
| $114M | 1.5% | 14,175,398 +1,408,450 | +11% | +$11.3M |
|
|
VRNA
19
Verona Pharma
VRNA
$9.16B
| $110M | 1.46% | 7,632,646 +1,314,656 | +21% | +$19M |
|
20
Day One Biopharmaceuticals
DAWN
$769M
| $108M | 1.43% | 7,871,721 +61,869 | +0.8% | +$853K |
|
21
4D Molecular Therapeutics
FDMT
$288M
| $107M | 1.42% | 5,098,211 +46,700 | +0.9% | +$980K |
|
22
ARS Pharmaceuticals
SPRY
$1.15B
| $92.4M | 1.22% | 10,860,977 | – | – |
|
23
Wave Life Sciences
WVE
$1.53B
| $90.8M | 1.2% | 18,202,009 | – | – |
|
|
LBPH
24
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $88.9M | 1.18% | 3,289,119 | – | – |
|
|
25
Arcellx
ACLX
$3.85B
| $88.5M | 1.17% | +1,604,014 | New | +$88.5M |
|